Evogene (EVGN) Other Accumulated Expenses (2012 - 2025)

Evogene has reported Other Accumulated Expenses for 14 years, with the latest figure at $449000.0 in Q4 2025.

• Quarterly Other Accumulated Expenses fell 58.39% year-over-year to $449000.0 in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $449000.0 (down 58.39% YoY) and the FY2025 annual result came in at $449000.0, down 58.39% from the prior year.
• Other Accumulated Expenses retreated to $449000.0 in Q4 2025 per EVGN's latest filing, from $645000.0 in the prior quarter.
• Over five years, Other Accumulated Expenses peaked at $1.6 million in Q4 2022 and troughed at $449000.0 in Q4 2025.
• A 5-year average of $997450.0 and a median of $1.0 million in 2023 frame the typical range for Other Accumulated Expenses.
• The sharpest annual moves came in 2023 and 2025: Other Accumulated Expenses surged 41.62% in 2023, then plunged 58.39% in 2025.
• Over 5 years, Other Accumulated Expenses stood at $1.5 million in 2021, then advanced by 6.45% to $1.6 million in 2022, then slumped by 36.98% to $1.0 million in 2023, then advanced by 5.89% to $1.1 million in 2024, then slumped by 58.39% to $449000.0 in 2025.
• According to Business Quant data, Other Accumulated Expenses over the past three periods registered $449000.0, $645000.0, and $520000.0 for Q4 2025, Q3 2025, and Q2 2025 respectively.